NEWS AND PRESS
PRESS RELEASE: CMS approves Reapplix clinical study for reimbursement coverage
Reapplix ApS (Reapplix), developers of the unique LeucoPatch® active wound therapy, have today announced that the Centers for Medicare and Medicaid Services (CMS) in the USA have approved Reapplix’s clinical research study protocol for Coverage with Evidence Development.
PRESS RELEASE: Reapplix announces appointment of Graeme Brookes as new CEO
Reapplix ApS (Reapplix), developers of the unique LeucoPatch active wound therapy, have appointed Graeme Brookes as Chief Executive Officer. Graeme’s appointment significantly strengthens the commercial capabilities of the management team and provides increased emphasis on implementing this promising technology into clinical use.
LeucoPatch support the work of the diabetic foot study group
To support the important work done by the Diabetic Foot Study Group (DFSG), Reapplix – the company behind The LeucoPatch – is a Silver sponsor of the yearly DFSG meeting.
LeucoPatch featured in Danish television
“Lise Tarnow, TV2 Lorry”: www.tv2lorry.dk/arkiv/2014/7/14?video_id=93064
The large randomized clinical trial of LeucoPatch speeds up
Clinical sites are continuously being added to the LeucoPatch RCT Recently sites in Lincoln, Dudley and Sheffield have joined us – welcome!
Large international randomized controlled trial on LeucoPatch started 2013
A study of more than 250 diabetic foot ulcer patients will be initiated in cooperation with principal investigators Dr. Löndahl, Dr. Game, Prof. Jeffcoate and Dr. Tarnow at several multidisciplinary team based clinical sites in UK, Denmark and Sweden.
Scandinavian multicenter study of LeucoPatch presentented at EWMA 2013
Final clinical data from the LeucoPatch diabetic foot ulcer study were presented by Clinical investigator Dr. Bo Jørgensen at the European Wound Management Association meeting held in Copenhagen.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.